Monitoring the efficiency of reversal on anti-Xa direct oral anticoagulants using point-of-care viscoelastic testing.
Andexanet alfa
Bleeding
DOAC
POC
Point-of-care
RVV-test
Reversal
VET
Viscoeleastic testing
Journal
Thrombosis journal
ISSN: 1477-9560
Titre abrégé: Thromb J
Pays: England
ID NLM: 101170542
Informations de publication
Date de publication:
08 Oct 2024
08 Oct 2024
Historique:
received:
22
06
2024
accepted:
26
09
2024
medline:
9
10
2024
pubmed:
9
10
2024
entrez:
8
10
2024
Statut:
epublish
Résumé
Bleeding events in patients receiving direct oral anticoagulation (DOAC) can be life-threatening even at therapeutic DOAC plasma concentrations, as anticoagulation impairs hemostasis and should therefore be identified immediately after hospital admission. The anticoagulatory effects of DOAC are typically not measurable in standard coagulation tests, such as PT or aPTT. Specific calibrated anti-FXa-tests allow specific drug monitoring, but they are too time-consuming for critical bleeding events and are commonly not available for 24 h/7 days in routine care. However, recent advances in point-of-care (POC) viscoelastic testing (VET) have shown a promising approach for rapid and quantitative detection of DOAC plasma concentrations using the Russell viper venom factor V activator (RVV for FXa-inhibitors) test or the ecarin clotting time (thrombin inhibitors). In acute bleeding situations, direct FXa inhibitors can be reversed by specific antidote andexanet alfa or hemostasis can be improved by prothrombin complex factor concentrates (PCCs). After reversal, confirmation of reversal efficacy is often requested, but no routine assays are currently available. Thus, the emergency management of bleeding DOAC patients is usually "blinded" with regard to reversal efficacy. POC VET laboratory assays might therefore also be helpful for measuring DOAC effects after reversal. We present a case series demonstrating the usefulness of RVV-clotting time post-DOAC reversal with andexanet alfa.
Identifiants
pubmed: 39379995
doi: 10.1186/s12959-024-00659-8
pii: 10.1186/s12959-024-00659-8
doi:
Types de publication
Journal Article
Langues
eng
Pagination
89Informations de copyright
© 2024. The Author(s).
Références
Rossini R, Quadri G, Rognoni A, Nardi F, Varbella F, Musumeci G. Use of DOACs in real-world challenging settings: a Delphi Consensus from Italian cardiologists. Minerva Cardioangiol. 2019;67(5):361–73.
doi: 10.23736/S0026-4725.19.04985-5
pubmed: 31343145
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, et al. : 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498.
doi: 10.1093/eurheartj/ehaa612
pubmed: 32860505
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr., Ellinor PT, Ezekowitz MD, Field ME, Furie KL, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the management of patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines and the heart rhythm society in collaboration with the Society of thoracic surgeons. Circulation. 2019;140(2):e125–51.
doi: 10.1161/CIR.0000000000000665
pubmed: 30686041
Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, Leavitt AD, Lee AYY, Macbeth F, Morgan RL, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927–74.
doi: 10.1182/bloodadvances.2020003442
pubmed: 33570602
pmcid: 7903232
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.
doi: 10.1016/S0140-6736(13)62343-0
pubmed: 24315724
Köhler C, Tittl L, Marten S, Naue C, Spindler M, Stannek L, Fache K, Beyer-Westendorf J. Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY. Thromb Res. 2022;215:37–40.
doi: 10.1016/j.thromres.2022.05.010
pubmed: 35623105
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.
doi: 10.1056/NEJMoa1107039
pubmed: 21870978
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.
doi: 10.1056/NEJMoa0905561
pubmed: 19717844
Ruoff C, Schöchl H, Fritsch G, Voelckel W, Zipperle J, Gratz J, Schmitt F, Oberladstätter D. DOAC plasma concentration upon hospital admission in a cohort of trauma patients. An observational real-life study. Eur J Trauma Emerg Surg 2023.
Lindhoff-Last E, Birschmann I, Kuhn J, Lindau S, Konstantinides S, Grottke O, Nowak-Göttl U, Lucks J, Zydek B, von Heymann C, et al. Pharmacokinetics of direct oral anticoagulants in emergency situations: results of the prospective Observational RADOA-Registry. Thromb Haemost. 2022;122(4):552–9.
doi: 10.1055/a-1549-6556
pubmed: 34256392
Benz AP, Xu L, Eikelboom JW, Middeldorp S, Milling TJ Jr., Crowther M, Yue P, Conley P, Lu G, Connolly SJ. Andexanet Alfa for specific anticoagulation reversal in patients with Acute bleeding during treatment with Edoxaban. Thromb Haemost. 2022;122(6):998–1005.
doi: 10.1055/s-0041-1740180
pubmed: 34996121
pmcid: 9251710
Pollack CV Jr., Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, et al. Idarucizumab for Dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377(5):431–41.
doi: 10.1056/NEJMoa1707278
pubmed: 28693366
Levi M, Moore KT, Castillejos CF, Kubitza D, Berkowitz SD, Goldhaber SZ, Raghoebar M, Patel MR, Weitz JI, Levy JH. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost. 2014;12(9):1428–36.
doi: 10.1111/jth.12599
pubmed: 24811969
Connolly SJ, Sharma M, Cohen AT, Demchuk AM, Członkowska A, Lindgren AG, Molina CA, Bereczki D, Toni D, Seiffge DJ, et al. Andexanet for factor xa inhibitor-Associated Acute Intracerebral Hemorrhage. N Engl J Med. 2024;390(19):1745–55.
doi: 10.1056/NEJMoa2313040
pubmed: 38749032
Heubner L, Mirus M, Vicent O, Güldner A, Tiebel O, Beyer-Westendorf J, Fries D, Spieth PM. Point of care coagulation management in anesthesiology and critical care. Minerva Anestesiol 2022.
Heubner L, Vicent O, Beyer-Westendorf J, Spieth PM. Bleeding management in patients with direct oral anticoagulants. Minerva Anestesiol. 2023;89(7–8):707–15.
pubmed: 37079285
Groene P, Wagner D, Kammerer T, Kellert L, Giebl A, Massberg S, Schäfer ST. Viscoelastometry for detecting oral anticoagulants. Thromb J. 2021;19(1):18.
doi: 10.1186/s12959-021-00267-w
pubmed: 33726769
pmcid: 7962229
Oberladstätter D, Voelckel W, Schlimp C, Zipperle J, Ziegler B, Grottke O, Schöchl H. A prospective observational study of the rapid detection of clinically-relevant plasma direct oral anticoagulant levels following acute traumatic injury. Anaesthesia. 2021;76(3):373–80.
doi: 10.1111/anae.15254
pubmed: 32946123
Douxfils J, Adcock DM, Bates SM, Favaloro EJ, Gouin-Thibault I, Guillermo C, Kawai Y, Lindhoff-Last E, Kitchen S, Gosselin RC. 2021 update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of direct oral anticoagulants. Thromb Haemost. 2021;121(08):1008–20.
doi: 10.1055/a-1450-8178
pubmed: 33742436
Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, Wirth D, Kaatz S. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol. 2019;94(6):697–709.
doi: 10.1002/ajh.25475
pubmed: 30916798
Calatzis AWM, Leyser H, Hipp Q, Spannagl M. ClotPro – a new generation viscoelastic whole blood coagulation analyzer. Hämostaseologie 2018(p.P013).
Calatzis A, Peetz D, Haas S, Spannagl M, Rudin K, Wilmer M. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol. 2008;130(3):446–54.
doi: 10.1309/Q0G21Y26UR0UHQ1A
pubmed: 18701419
Groene P, Wagner D, Kammerer T, Kellert L, Giebl A, Massberg S, Schafer ST. Viscoelastometry for detecting oral anticoagulants. Thromb J. 2021;19(1):18.
doi: 10.1186/s12959-021-00267-w
pubmed: 33726769
pmcid: 7962229
Lu G, Conley PB, Leeds JM, Karbarz MJ, Levy GG, Mathur VS, Castillo J, Crowther M, Curnutte JT. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. Blood Adv. 2020;4(4):728–39.
doi: 10.1182/bloodadvances.2019000885
pubmed: 32092140
pmcid: 7042988
Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor xa. Nat Med. 2013;19(4):446–51.
doi: 10.1038/nm.3102
pubmed: 23455714
Blackburn M: Four-factor prothrombin complex concentrate administration after expanding intracranial hemorrhage status post administration of andexanfa. et al. 2022, 62:144.e141-144.e143.
Orban JE 3rd, Ruckel C, Harlan S. Concomitant andexanet alfa and 4 F-PCC for factor xa inhibitor associated intracranial hemorrhage. Clin Neurol Neurosurg. 2023;233:107908.
Milling TJ Jr., Middeldorp S, Xu L, Koch B, Demchuk A, Eikelboom JW, Verhamme P, Cohen AT, Beyer-Westendorf J, Gibson CM, et al. Final study report of Andexanet Alfa for major bleeding with factor xa inhibitors. Circulation. 2023;147(13):1026–38.
doi: 10.1161/CIRCULATIONAHA.121.057844
pubmed: 36802876
Zipperle J, Schmitt FCF, Schöchl H. Point-of-care, goal-directed management of bleeding in trauma patients. Curr Opin Crit Care. 2023;29(6):702–12.
doi: 10.1097/MCC.0000000000001107
pubmed: 37861185